# Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

> **NCT00130286** · PHASE1,PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 77 (actual)

## Conditions studied

- HIV-Associated Lipodystrophy Syndrome
- Insulin Resistance
- HIV Infections
- Metabolic Syndrome X
- Body Weight Changes

## Interventions

- **DRUG:** Rosiglitazone
- **DRUG:** Recombinant human growth hormone + rosiglitazone

## Key facts

- **NCT ID:** NCT00130286
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2014-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00130286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00130286, "Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00130286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*